Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
about
Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipientsEmerging therapies for hepatitis CVirocidal activity of Egyptian scorpion venoms against hepatitis C virus.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.Vertical transmission of hepatitis B virus: challenges and solutionsInvestigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsPrevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus.Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.New treatments for chronic hepatitis C: an overview for paediatricians.Beclabuvir for the treatment of hepatitis C.Asunaprevir for hepatitis C: a safety evaluation.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?Discontinued drugs in 2012 - 2013: hepatitis C virus infection.Persistent replication of a hepatitis C virus genotype 1b-based chimeric clone carrying E1, E2 and p6 regions from GB virus B in a New World monkey.Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
P2860
Q26795595-F128BF81-D2C8-4D8D-ABC6-41734D4F700BQ26853642-B3731720-905A-49BD-BF45-46CD99D275C4Q30389258-9DF36102-4932-4E70-8162-C17DB8D8AA0EQ31051529-5F1114B8-2342-47F0-9626-962C9CEC5622Q33735206-43CF20ED-9172-4F30-910C-A1FB5FF55C82Q33774099-EB246AE6-49EE-42CF-8D19-07781A2D31A2Q34420891-5587CC5E-94D5-4057-AF0B-D9314C0257EAQ34424151-618C605E-48F3-4AF2-9580-FC829957F1C0Q35141547-6EA346CA-29E1-414B-997D-E44BBCC03904Q35146790-3A6626DF-B2DF-4107-AD5C-04AE3B3FE92FQ38212793-851F360B-0F63-4E21-9ECB-01A207A8D6CCQ38233860-88481D5E-504D-4B2D-90D8-F9B83BC22539Q38235178-05EAAD0A-9CB9-45A0-94EF-07B8F9B7DF7FQ38237281-90CDE68D-6541-44CB-B50B-FE7BD29844E7Q38282842-648B7642-219C-4F5A-A6A8-FDF5EE5519CEQ38544196-D8DF8AD2-BCB9-4F79-A405-F54F297D62D3Q38578458-49763105-3E8A-4638-8C9C-4CA9F3FB2042Q38779980-B07DE427-EF95-4419-B63B-A64A190AFDADQ38893104-93DA201D-D1A7-49B8-B187-9B9A75B0BE44Q39010715-556D474B-CAA7-4E5F-B76A-2B076FF5CDE9Q39100351-68708B95-CA39-4D3C-BB9C-D8FCB3950643Q40244787-F32EA553-2EFA-4C32-9B27-327B40BBAE04Q41248646-9BA005BE-7E66-4517-96C9-507EDC88D7F9Q47593083-82B854E0-65AC-4E3A-A800-511628265A92
P2860
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
@en
type
label
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
@en
prefLabel
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
@en
P2093
P50
P1476
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A
@en
P2093
P304
P356
10.2174/0929867321666131228222215
P577
2014-01-01T00:00:00Z